Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
April 27, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...
Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo
November 16, 2016 09:05 ET
|
Novan, Inc.
Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model Effect Relates to Multiple Inflammatory Skin Diseases MORRISVILLE, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the...